EUPHAS2

EUPHAS 2 is a patient registry for the collection of clinical data from patients undergoing polymyxin B hemoperfusion therapy (PMX-HP, medical device Toraymyxin®, Toray Medical Ltd, Japan)... Toraymyxin® was marketed in Japan in 1994 and in Europe in 1998. The specific therapeutic target is the patient with endotoxin-mediated septic shock who is unresponsive to standard therapy. Outside Japan, Italy is the primary user of Toraymyxin®.